49results about "Reference solutions" patented technology

A method of quality control of a specimen prepared from a sample, includes: (S1) setting, from a control index information (MII) in which a plurality of indexes for the specimen are respectively associated with control values corresponding to the plurality of indexes, at least one index to be used for quality control of the specimen; (S3) obtaining a feature value relating to the at least one index from image data of the specimen; and (S5) outputting quality control information of the specimen based on the feature value and a control value associated with the at least one index.

An IROA Matrix of metabolite compounds is disclosed. Each of whose compounds has a molecular weight of 2000 AMU or less, and is present as first and second isotopomers that are equally present at two predetermined isotopomeric balances, and contain 2 to 10% of a first isotope, and 90 to 98% of a second isotope, respectively. A reagent pair for transforming a natural abundance mass spectral analysis metabolite sample into an IROA sample is also disclosed and comprises two reactively identical reagents that constitute first and second isotopomers containing 2 to 10% of a first isotope, and 90 to 98% of a second isotope, respectively. Each of the reagent pair contains the same reactive group that reacts with and bonds to a functional group of one or more compounds present in a composition of biologically-produced metabolite compounds. Methods of making and using the above and related materials are also disclosed.

Disclosed herein are embodiments of a method for calibrating a group of analyzer units, each analyzer unit of the group of analyzer units configured for determining an amount of an analyte in plasma of a whole-blood sample. The method comprises: providing a plurality of calibration whole-blood samples, the plurality of calibration whole-blood samples including calibration whole-blood samples having respective hematocrit levels, for each calibration whole-blood sample of the plurality of calibration whole-blood samples: measuring a hematocrit measurement value indicative of the hematocrit level of said calibration whole-blood sample, measuring a whole-blood measurement value indicative of an amount of the analyte in the calibration whole-blood sample using at least one calibration analyzer unit of said group of analyzer units, measuring a plasma measurement value indicative of an amount of the analyte in plasma of said calibration whole-blood sample, and computing a ratio between the whole-blood measurement value and the plasma measurement value; generating a nonlinear functional relationship between the computed ratios and the corresponding hematocrit measurement values by curve fitting of a nonlinear function parametrized by one or more calibration parameters, the curve fitting resulting in respective parameter values of the one or more calibration parameters; storing a representation of the fitted nonlinear function in each analyzer unit of the group of analyzer units to allow each analyzer unit of the group of analyzer units to compute a hematocrit correction factor.

The present disclosure provides a peptide library comprising stable isotope-labeled (SIL) peptides, wherein the peptides comprise or consist of the sequences according to Table A, Table B, or Table C.

Disclosed is a method of diagnosing multiple sclerosis (MS), wherein a blood sample from a patient is incubated with a DNA-replication associated (REP) protein. The present invention relates to a DNA-replication-associated (Rep) protein for use in the diagnosis of multiple sclerosis (MS), wherein (a) Aan increased amount of Rep protein or fragments thereof in the sample as compared to an amount in a control sample; or an increased amount of anti-Rep protein antibodies with antigen in a sample from a subject as compared to an amount in a control sample correlates with a diagnosis of MS, wherein the Rep protein is MSBI1 Rep or MSBI2 Rep.

Disclosed herein are methods, devices and kits suitable for high throughput screenings of extracellular pyridine nucleotide levels, such as NAD+ levels which are suitable for monitoring pyridine nucleotide induced slowdown of not only pathogenesis of multiple systemic diseases but also aging. In particular, assaying methods quantifying extracellular pyridine nucleotide(s), such as NAD+, in the low micromolar to the low nanomolar range in a sample that may have been subjected to long term storage are disclosed using a two-step enzymatic cycling reaction employing an oxidoreductase such as alcohol dehydrogenase. A modified revised simulated body fluid is also disclosed that is employed as a standard matrix to optimise enzymatic activity, linearity and / or sensitivity of the methods, devices and kits.

Embodiments described herein generally relate to systems and methods for processing mass spectrometry samples. Aspects of the disclosure include systems and methods for processing samples. Additionally, embodiments of the disclosure can also include systems and methods for sample analysis. Various embodiments include data analysis systems and methods for comparing data across samples and sample runs. Data analysis systems can run normalization methods for normalizing raw abundance mass spectrometry data. In some aspects, the normalized data can be used as input for predictive models.

The disclosure features calibration fluids that include a plurality of beads, such as cellulose, silica, poly(methyl-methacrylate) (PMMA), melamine, cross-linked agarose, polyvinylacetate (PVA), and / or polystyrene beads, where the beads are sized and colored to represent at least one type of blood cell; and a carrier fluid, that can include a polymer or polymerizing matrix, e.g., a water-soluble resin, e.g., an acrylic or polyurethane water-soluble resin or a starch or a cellulose, serum, and / or one or more or sugars. The disclosure also features methods of using the calibration fluids to calibrate automated sample preparation systems, such as automated hematology analyzer systems, e.g., image-based hematology analyzer systems.

This invention describes a method for preparation of stable hematology reference materials by producing synthetic hydrogel blood cell surrogates, which mimic human blood components in size, morphology, performance and functionality when analyzed using an automated hematology analyzer employing multiple detection technologies. Different hydrogel particles can be combined and mixed to prepare multi-parameter and multi-level hematology reference materials, which could be used for calibration, linearity verification, proficiency evaluation, and routine performance monitoring of modern automated hematology analyzers. These hydrogel particles can also be combined with processed and stabilized human blood components to prepare the reference materials of this invention.

A method that evaluates metastatic behavior, apoptotic behavior, and / or cancer therapy response efficiency. The method has steps. The method has steps and some of those steps are: Providing a first cell culture having cancer cells and a second cell culture. There is no physical contact between the first cell culture and the second cell culture. Co-culturing the first cell culture and the second cell culture having no physical contact therebetween under a mutual headspace. Determining concentrations of VOCs in the mutual headspace. Comparing the concentrations of the VOCs in the mutual headspace to the concentrations of VOCs in a control sample. Identifying a set of VOCs indicative of cell-to-cell signaling in cancer cells in the mutual headspace wherein the VOCs have concentrations that are significantly different as compared to the control sample. And evaluating metastatic behavior, apoptotic behavior, and / or cancer therapy response efficiency using the set of VOCs identified above.

To provide reliable positive and negative IHC controls that are highly sensitive, specific, and adaptable to a wide range of targets, including targets for which no suitable biological controls exist.SOLUTION: Synthetic controls include a solid antigen / carrier protein gel comprising purified antigen (e.g., in a known amount) and a carrier protein, such as a serum albumin protein (e.g., a serum albumin protein), an egg white protein or a mixture of egg white proteins, gelatin, or polylysine. In some embodiments, the purified antigen is cross-linked to a carrier protein in a solid antigen / carrier protein gel.SELECTED DRAWING: Figure 3-1

The present invention provides a quality control solution and its use. Said quality control solution includes a buffer, a polymer, EDTA or a salt thereof, a preservative, a blood simulated dye and an analyte, said polymer being selected from PEG 2000~ 6000, propylene glycol, glycerol, or a combination thereof. The quality control solution of the present invention can be for performing quality control of at least one analyte. It does not require refrigeration, freezing or lyophilization, can be placed at room temperature, is relatively convenient to use and can be used in fields of immunological detection, biochemical detection and electrochemical detection.

A composition comprising a plurality of hydrogel particles, the plurality of hydrogel particles having substantially the same diameter, but each subclass of particles from the plurality of hydrogel particles having a different associated value of one or more passive optical properties that can be deconvoluted using cytometry instrumentation. Each hydrogel particle from the plurality of hydrogel particles can be functionalized with a different biochemical or chemical target from a set of targets. A method for preparing hydrogel particles includes forming droplets and polymerizing the droplets, optionally with functionalization.

The present disclosure provides a preservation liquid for calcium oxalate dihydrate crystals, which is a solution containing an anionic surfactant or a non-ionic surfactant. Also provided is a method for preserving calcium oxalate dihydrate crystals, the method including preserving calcium oxalate dihydrate crystals in a solution containing an anionic surfactant or a non-ionic surfactant.

An erythrocyte control composition comprising one or more populations of dissolvable hydrogel particles having an impedance substantially similar to that of human erythrocytes of average diameter, and a population of hemoglobin molecules or a population of dye molecules having an absorbance substantially similar to hemoglobin, wherein (i) and / or (ii) are present in an amount corresponding to a normal blood sample or a medical condition, or (i) and (ii) are present in a ratio corresponding to a normal blood sample or a medical condition, is provided.

Disclosed herein are embodiments of a method for calibrating a group of analyzer units, wherein each analyzer unit of the group of analyzer units is configured to determine the amount of an analyte in the plasma of a whole blood sample. The method includes providing a plurality of calibration whole blood samples, the plurality of calibration whole blood samples including calibration whole blood samples having respective hematocrit values; for each calibration whole blood sample of the plurality of calibration whole blood samples, measuring a hematocrit measurement value indicative of the hematocrit value of the calibration whole blood sample, measuring a whole blood measurement value indicative of the amount of the analyte in the calibration whole blood sample using at least one calibration analyzer unit of the group of analyzer units, measuring a plasma measurement value indicative of the amount of the analyte in the plasma of the calibration whole blood sample, and calculating a ratio between the whole blood measurement value and the plasma measurement value; generating a non-linear functional relationship between the calculated ratio and the corresponding hematocrit measurement value by curve fitting of a non-linear function parameterized by one or more calibration parameters, the curve fitting resulting in respective parameter values for each of the one or more calibration parameters; and storing an expression of the fitted non-linear function in each analyzer unit of the group of analyzer units to enable each analyzer unit of the group of analyzer units to calculate a hematocrit correction factor.

Please add the following Abstract on a separate sheet after the claims section of the subject application.An in-vitro diagnostic (IVD) analyzer 200 comprising at least one sensor 212 located in a flow-through sensor path 211 of detecting unit and requiring at least one oxygenated calibration fluid 221′, 222′ for calibration is herein disclosed. The IVD analyzer 200 further comprises a fluid-supply unit 220 comprising at least one deoxygenated calibration fluid 221, 222, a fluid-selection valve 230 and at least one oxygenation tubing 215, 216 having two ends connected to the fluid-selection valve 230 as a loop, wherein the oxygenation tubing 215, 216 comprises oxygen-permeable walls, and wherein the IVD analyzer 200 further comprises a pump 240 and a controller 250 configured to control the pump 240 and the fluid-selection valve 230 for transporting deoxygenated calibration fluid 221, 222 into the oxygenation tubing 215, 216, to wait a predetermined time required for oxygenation of the deoxygenated calibration fluid 221, 222 via oxygen uptake from ambient air through the tubing walls, and to transport the thereby obtained oxygenated calibration fluid 221′, 222′ into the sensor path 211 for calibration of the at least one sensor 212. A respective automatic method of calibrating at least one sensor 212 is herein also disclosed.

This invention relates to a method for evaluating the wound-healing efficacy of mesenchymal stem cell (MSC) populations. Furthermore, this invention relates to a method for selecting MSCs for generating stem cell populations under cGMP conditions, and a method for selecting MSC populations for generating stem cell populations for subsequent drug administration. Additionally, this invention relates to a method for selecting MSC populations for generating a master cell bank, and a method for identifying tissues suitable as starting materials for generating MSC populations for drug use. The method includes measuring the levels of at least two proteins selected from angiopoietin-1 (Ang-1), transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), and hepatocyte growth factor (HGF) secreted by MSCs into the culture medium.

A method of generating smear quality control information according to an embodiment may include: obtaining a plurality of image data from a plurality of smears, respectively; obtaining, from the plurality of image data, feature values each of which reflects a staining state of each smear; and generating quality control information based on the feature values.

Disclosed herein are compositions comprising oxygen, a sugar or sugar alcohol, and an amino acid, wherein the amino acid is present in an amount sufficient to stabilize the oxygen. Also provided are aqueous diagnostic quality controls or calibration reagents and methods of stabilizing oxygen in a liquid solution.

Disclosed are methods, libraries, and samples for quantifying a target analyte in a laboratory sample including the target analyte. The methods typically include the step of estimating the amount of the target analyte in the laboratory sample from mass spectrometric data including signal intensities for the target analyte and one or more internal standards, where the mass spectrometric data are an output of a mass spectrometric analysis of a target sample produced from the laboratory sample and a predetermined amount of the one or more internal standards. The present disclosure also provides a method for analyte quantification. The method comprises adding one or more calibrators to a sample comprising one or more analytes; applying mass spectrometry (MS) to the sample; and using a trained machine learning model to determine an absolute concentration of the one or more analytes.

The preparation and use of systems to provide surrogate whole blood controls using coagulation modifiers to simulate human whole blood in coagulation assays are disclosed.

An aspect of the present disclosure provides a solution for transporting or storing a body fluid sample, the solution including a substance selected from the group consisting of kanamycin, G418, streptomycin, maltotriose, N-acetylmuramic acid, and glucose as an active ingredient.

Embodiments described herein generally relate to systems and methods for processing mass spectrometry samples. Aspects of the disclosure include systems and methods for processing samples. Additionally, embodiments of the disclosure can also include systems and methods for sample analysis. Various embodiments include data analysis systems and methods for comparing data across samples and sample runs. Data analysis systems can run normalization methods for normalizing raw abundance mass spectrometry data. In some aspects, the normalized data can be used as input for predictive models.

To provide methods of screening condensate-associated specificity, and uses thereof.SOLUTION: Methods of identifying a compound, such as a test compound, and applications thereof are provided. For example, methods of identifying a compound that preferentially affects, increases, or decreases a level of association of a macromolecule with one or more target condensates or methods of identifying a compound that preferentially causes a macromolecule to associate or disassociate with one or more target condensates are provided. Additionally, methods of designing and / or identifying and / or making a compound, or portion thereof, with a desired characteristic are provided.SELECTED DRAWING: Figure 7

Provided herein are compositions and methods for fluorescence activated cell analysis of white blood cell populations. The compositions and methods enable thorough characterization each subpopulation of a greater cell population of leukocytes. Additionally, the biomarker-based standards and methods of are expedited as compared to the conventional technology and produce a positive control test material that reduces the cost, expedites the process, and improves the outcome of fluorescence activated cell analysis of blood cell populations.

Epileptic seizures, NES, NS, PNES or NEE are difficult to diagnose and are often difficult to distinguish from several conditions with similar presentations, and therefore, diagnosis of seizures is often a long, expensive, and unreliable process. This invention provides biomarkers for identifying and monitoring seizures and epilepsy, ES, NES, NS, PNES or NEE assays for measuring and assessing biomarker concentration, predictive models based on biomarkers and computational systems for diagnosing, monitoring and predicting therapeutic efficacy associated with seizures and epilepsy, ES, NES, NS, PNES or NEE in all clinical and healthcare settings. Diagnostic and treatment methods, systems, kits, and predictive models provided herein, provide quantitative and / or qualitative assessment in order to allow patients to proceed immediately to diagnostic and / or treatment protocols, and assess therapeutic treatment effectiveness.

A method of generating smear quality control information according to an embodiment may include: obtaining a plurality of image data from a plurality of smears, respectively; obtaining, from the plurality of image data, feature values each of which reflects a staining state of each smear; and generating quality control information based on the feature values.

Methods for quantifying surface markers on extracellular vesicles are provided. Aspects of the methods include comparing the mean fluorescence intensity of a surface marker of interest (surface marker MFI) of a labeled extracellular vesicle (EV) sample to a calibration curve obtained from a liposome calibration composition to quantify the surface marker on the extracellular vesicles of the EV sample. Compositions for practicing embodiments of the invention are also provided.